1. Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma
    Mehrdad Asghari Estiar et al, 2017, Cancer Biomarkers CrossRef
  2. VS-5584, a PI3K/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas in vitro and in vivo
    Yun Chen et al, 2021, Journal of Pediatric Surgery CrossRef
  3. Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma
    Venugopal Gunda et al, 2020, Cancers CrossRef
  4. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro
    Olga Piskareva et al, 2015, Cancer Letters CrossRef
  5. Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells
    Miguel Rodrigo et al, 2019, Cells CrossRef
  6. MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in NMYC Amplified Neuroblastoma Cell Lines
    Barbara Feriancikova et al, 2021, International Journal of Molecular Sciences CrossRef
  7. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
    Huiyuan Zhang et al, 2015, Apoptosis CrossRef
  8. Targeting succinate:ubiquinone reductase potentiates the efficacy of anticancer therapy
    Björn Kruspig et al, 2016, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
  9. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines
    Nevim Aygun et al, 2018, Molecular Medicine Reports CrossRef